Edotreotide yttrium Y-90
Also known as: 90Y-DOTATOC, DOTA-Tyr3-octreotide Y-90, DOTA‑(D‑Phe1)‑Tyr3‑Octreotide, DOTATOC, Edotreotide, OctreoTher, SOM230 radiolabeled analogue (distinct), Y-90 DOTA-TOC, Y-90 edotreotide
Source Edotreotide yttrium Y-90 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Edotreotide yttrium Y‑90 (90Y‑DOTATOC) is a DOTA‑conjugated octreotide analog labeled with the β‑emitter yttrium‑90, used in peptide‑receptor radionuclide therapy for somatostatin‑receptor positive neuroendocrine tumors.
Mechanism of Action
High‑affinity agonist of somatostatin receptor subtype 2; after binding the peptide‑receptor complex is internalized delivering β‑particles from 90Y to tumor cells.
Routes of Administration
Goals & Uses
- Symptom control in functional NETsSymptom ManagementModerate
- Tumor downsizing prior to surgeryOncologyModerate
- Treatment of somatostatin receptor-positive neuroendocrine tumorsOncologyHigh
- Neuroendocrine tumor therapyOncologyModerate
- Metastatic paraganglioma / pheochromocytomaOncologyLow
Contraindications
- Hepatic decompensation / liver metastases >70% liver replacementHepaticModerate
- Severe renal impairmentOrganHighKidney function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
- Hypersensitivity to DOTA-TOC or somatostatin analoguesImmunologicHigh
- Severe bone marrow suppressionHematologicHigh
Adverse Effects
- Myelosuppression (thrombocytopenia, leukopenia)HematologicCommon
- Nausea/vomitingGastrointestinalCommon
- Hematologic toxicity (anemia, thrombocytopenia, leukopenia)HematologyCommon
- Nausea and vomitingGastrointestinalCommon
- FatigueGeneralCommonLow energy or tiredness
- Radiation-induced hepatotoxicityHepaticUncommon
- Secondary myelodysplastic syndrome / leukemiaHematologicRare
- NephrotoxicityRenalUncommon
Drug Interactions
- Nephrotoxic agents (e.g., aminoglycosides, NSAIDs)Moderate
- Nephrotoxic agents (aminoglycosides, NSAIDs, contrast agents)High
- Myelosuppressive chemotherapyModerate
- Long-acting somatostatin analogues (octreotide LAR, lanreotide)Moderate
Population Constraints
- Patients with prior external beam radiation to kidneys or bone marrowPrior TherapyRelative
- Pediatric patientsAgeRelative
- Elderly patients (>70 years)AgeRelative
- Patients with renal impairment (GFR <40 mL/min)RenalRelative
Regulatory Status
- European UnionInvestigationalUsed under clinical trial protocols for NETs.
- United StatesUnapprovedAvailable only via IND for research.
- United KingdomUnknownPost-Brexit regulatory status uncertain; likely available through specialist centers on named-patient or compassionate use basis.
Approved in Switzerland and used under various national regulatory frameworks in Europe. Not FDA-approved in the United States; Lutathera (Lu-177 DOTATATE) is the FDA-approved PRRT. EMA approval status has been complex; OctreoTher was approved in Switzerland and used under compassionate/named-patient programs across Europe.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Edotreotide yttrium Y-90?
Edotreotide yttrium Y‑90 (90Y‑DOTATOC) is a DOTA‑conjugated octreotide analog labeled with the β‑emitter yttrium‑90, used in peptide‑receptor radionuclide therapy for somatostatin‑receptor positive neuroendocrine tumors.
What is Edotreotide yttrium Y-90 used for?
Edotreotide yttrium Y-90 is educationally associated with: Symptom control in functional NETs, Tumor downsizing prior to surgery, Treatment of somatostatin receptor-positive neuroendocrine tumors, Neuroendocrine tumor therapy, Metastatic paraganglioma / pheochromocytoma. Educational only — not medical advice.
How is Edotreotide yttrium Y-90 administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Edotreotide yttrium Y-90?
Reported adverse effects include: Myelosuppression (thrombocytopenia, leukopenia), Nausea/vomiting, Hematologic toxicity (anemia, thrombocytopenia, leukopenia), Nausea and vomiting, Fatigue, Radiation-induced hepatotoxicity, Secondary myelodysplastic syndrome / leukemia, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Edotreotide yttrium Y-90?
Recorded contraindications: Hepatic decompensation / liver metastases >70% liver replacement, Severe renal impairment, Pregnancy, Breastfeeding, Hypersensitivity to DOTA-TOC or somatostatin analogues, Severe bone marrow suppression. Consult a qualified clinician before use.